Costa Rica
Tuberculosis profile
Population  2013 4.9 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.033 (0.03–0.035) 0.67 (0.61–0.73)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.16 (0.13–0.2)
Prevalence  (includes HIV+TB) 0.72 (0.34–1.2) 15 (7–25)
Incidence  (includes HIV+TB) 0.56 (0.49–0.64) 11 (10–13)
Incidence (HIV+TB only) 0.05 (0.044–0.057) 1 (0.91–1.2)
Case detection, all forms (%) 74 (64–83)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.5 (0.42–3.9) 4.5 (0.12–23)
MDR-TB cases among notified pulmonary
TB cases
5 (2–14) 1 (0–5)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 330   14
Pulmonary, clinically diagnosed 29   0
Extrapulmonary 32   5
       
Total new and relapse 410    
Previously treated, excluding relapses 7    
Total cases notified 417    
Among 408 new and relapse cases:
32 (8%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 10 (3%) 0 (0%) 10
Laboratory-confirmed RR-/MDR-TB cases     4
Patients started on MDR-TB treatment     1
TB/HIV 2013 Number (%)
TB patients with known HIV status 402 (96)
HIV-positive TB patients 36 (9)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 36 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 86
Previously treated cases, excluding relapse, registered in 2012 88
HIV-positive TB cases, all types, registered in 2012 59
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 14.9
Drug susceptibility testing (per 5 million population) 1.1
Sites performing Xpert MTB/RIF 4
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-02 Data: www.who.int/tb/data